Alaunos Therapeutics (TCRT)
NASDAQ:TCRT
Holding TCRT?
Track your performance easily

Alaunos Therapeutics (TCRT) Income Statement

672 Followers

Alaunos Therapeutics Income Statement

Last quarter (Q2 2024), Alaunos Therapeutics's total revenue was $4.00K, a decrease of 0.00% from the same quarter last year. In Q2, Alaunos Therapeutics's net income was $-1.13M. See Alaunos Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 6.00K$ 5.00K$ 2.92M$ 400.00K$ 57.50M-
Cost of Revenue
------
Gross Profit
$ 6.00K$ 5.00K$ 2.90M$ 400.00K$ 57.50M-
Operating Expense
$ 19.53M$ 34.27M$ 38.03M$ 77.95M$ 80.36M$ 57.86M
Operating Income
$ -19.52M$ -34.27M$ -35.10M$ -77.55M$ -80.36M$ -57.86M
Net Non Operating Interest Income Expense
-$ -1.92M$ -3.15M$ -1.19M--
Other Income Expense
$ -4.07M$ -4.73M$ 662.00K$ 13.00K$ -385.00K$ -813.00K
Pretax Income
$ -18.89M$ -35.14M$ -37.73M$ -77.27M$ -79.98M$ -57.05M
Tax Provision
------
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -19.13M$ -35.14M$ -37.73M$ -77.27M$ -79.98M$ -117.80M
Basic EPS
$ -5.64$ -22.00$ -2.55$ -5.55$ -5.70$ -0.70
Diluted EPS
$ -5.64$ -22.00$ -2.55$ -5.55$ -5.70$ -0.70
Basic Average Shares
$ 35.22M$ 1.60M$ 14.48M$ 14.29M$ 13.98M$ 167.95M
Diluted Average Shares
$ 35.22M$ 1.60M$ 14.48M-$ 13.98M$ 167.95M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 19.53M$ 28.50M$ 38.16M$ 77.95M$ 80.36M$ 57.86M
Net Income From Continuing And Discontinued Operation
$ -19.13M$ -35.14M$ -37.73M$ -78.75M$ -79.98M$ -117.80M
Normalized Income
$ -2.40M$ -14.87M-$ -56.05M--
Interest Expense
------
EBIT
$ -11.65M$ -33.22M$ -34.58M$ -77.56M$ -79.98M$ -57.05M
EBITDA
$ -10.74M$ -30.90M$ -31.82M$ -74.97M$ -78.85M$ -56.42M
Currency in USD

Alaunos Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis